K. Sleegers

Discipline

Psychologie (7) Histoire, Philosophie et Sociologie des sciences (2) Anthropologie biologique (1)

Type de document

Articles (24)

Co-auteur

Date

Source

Mot-clé

Alzheimer's disease (24) biomarqueur (16) Human beings (16) Biochemical markers (15) maladie (13) Dementia (13) maladie (13) association (12) information (12) Apolipoprotein E (12) Amyloid (12) Social groups (12) risque (11) Risk (11) Cerebrospinal fluid (11) plasma (11) protéine (10) Proteins (10) analyse (9) âge (9) Age (9) Age (9) Analysis (9) cohorte (9) Performance (8) Mild cognitive impairment (8) Performance (8) Weights and measures (7) Brain (7) cerveau (7)

Documents écrit par K. Sleegers (24) | parle de K. Sleegers (0)

Paired plasma lipidomics and proteomics analysis in the conversion from mild cognitive impairment to Alzheimer's disease.
T. Naccache et al.
Multivariate GWAS of Alzheimer's disease CSF biomarker profiles implies GRIN2D in synaptic functioning.
A. Neumann et al. (4 oct. 2023)
Multiancestry analysis of the HLA locus in Alzheimer's and Parkinson's diseases uncovers a shared adaptive immune response mediated by HLA-DRB1*04 subtypes.
Y. Le Guen et al. (5 sept. 2023)
Multiomics profiling of human plasma and cerebrospinal fluid reveals ATN-derived networks and highlights causal links in Alzheimer's disease.
L. Shi et al.
Whole-exome rare-variant analysis of Alzheimer's disease and related biomarker traits.
F. Küçükali et al.
Genetic Associations Between Modifiable Risk Factors and Alzheimer Disease.
J. Luo et al. (1 mai 2023)
Author Correction: Common variants in Alzheimer's disease and risk stratification by polygenic risk scores.
I. de Rojas et al. (9 févr. 2023)
Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers.
I.E. Jansen et al.
Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease.
P.J. Visser et al. (13 mai 2022)
Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation.
A. Neumann et al.
New insights into the genetic etiology of Alzheimer's disease and related dementias.
C. Bellenguez et al.
Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease.
P.J. Visser et al. (28 mars 2022)
Predicting AT(N) pathologies in Alzheimer's disease from blood-based proteomic data using neural networks.
Y. Zhang et al. (2022)
Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset.
J. Homann et al. (2022)
Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort.
J. Xu et al. (3 nov. 2021)
Common variants in Alzheimer's disease and risk stratification by polygenic risk scores.
I. de Rojas et al. (7 juin 2021)
Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies.
L. Shi et al. (2021)
Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset.
S. Hong et al. (22 nov. 2020)
Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology.
L. Shi et al. (2020)
Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort.
S. Westwood et al. (2020)
Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay.
L. Shi et al.
Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort.
M. Kim et al.
A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort.
D. Stamate et al. (2019)
The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics.
I. Bos et al. (6 juil. 2018)